Fig. 1From: Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II studyKaplan-Meier curves showing disease-free survival (DFS). The 3-year DFS rate was 70.1% (60.8–78.0%)Back to article page